EPHB4 and neoplasm: It is possible that “leaky” tyrosine kinase inhibitors may also interact with EphB4, blocking the tumour suppressive signaling pathways and this may contribute to resistance seen in tumours that co-express EphB4 with the intended target receptor [46–47].